Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Sarcoma 1Gynecologic 1

Conditions

Pancreatic Neoplasms 3Colorectal Neoplasms 3Sarcoma 2Rectal Neoplasms 2Neoplasm Metastasis 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Ovarian Neoplasms 1Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1

Interventions

Cetuximab 44Oxaliplatin 39Irinotecan 38Fluorouracil 36Capecitabine 36Bevacizumab 36pembrolizumab 35Leucovorin 34Nivolumab 21Gemcitabine 17regorafenib 13Panitumumab 12IFL protocol 12Folfox protocol 12Cyclophosphamide 12Pemetrexed 11Cisplatin 11tislelizumab 9Paclitaxel 9HMPL-013 9Carboplatin 9130-nm albumin-bound paclitaxel 8durvalumab 7Specimen Handling 7Docetaxel 7trametinib 6Trifluridine 6Ipilimumab 6Drug Therapy 6trifluridine tipiracil drug combination 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Colorectal Neoplasms × conatumumab × Clear all
NCT00819169 2024-08-20

QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

NantCell, Inc.

Phase 1/2 Terminated
89 enrolled 20 charts
GastrointestinalGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT00625651 2014-04-25

Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer

Amgen

Phase 1/2 Completed
202 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00630786 2014-02-06

Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study

Amgen

Phase 1/2 Completed
53 enrolled 13 charts
Gastrointestinal

Colonic Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡